Kenn Samala (@KSamalaMD) header
Kenn Samala (@KSamalaMD) profile picture

Kenn Samala

@KSamalaMD

🩺🧬Internal Medicine-Medical Oncology. @pghoncology 🇵🇭 🫁Thoracic Oncology Fellowship at Cross Cancer Institute. @crosscancer50 🇨🇦 @PSO1964 Vice-President, 2025

 Edmonton, Alberta
fb.com/dockennsamala
Joined February 2022
  • Tweets541
  • Following166
  • Followers131
Kenn Samala retweeted
Aakash Desai (@ADesaiMD) profile picture
Aakash Desai@ADesaiMDOct 23
1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO 5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes. The question each one answers 🧵 #LCSM @LungCancerRx @OncoAlert @oncodaily
Image from Aakash Desai (@ADesaiMD)
1
8
17
1,823
Kenn Samala retweeted
gilberto lopes (@GlopesMd) profile picture
gilberto lopes
@GlopesMdOct 21
Five lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signals. Full data matter: survival, CNS activity, toxicity and quality of life. Figure separates published evidence from sponsor toplines. #LCSM
Image from gilberto lopes (@GlopesMd)
5
31
1
73
4,636
#ESMOAI25: Explore the latest AI-driven innovations in #oncology, brought to you by the #ESMOAmbassadors. Join the conversation on digital transformation in #CancerCare. #HealthAI 🔗 ow.ly/4V6z50XkYE6
Image from ESMO - Eur. Oncology (@myESMO)
9
5
17
1,945
Characterization of adenosquamous NSCLC and carcinosarcoma from @TheShieldsLab now @JTOonline. Actionable alterations (including METex14, EGFR, KRAS G12C, ALK, RET) seen in 37% of adenosquamous and in 17% of carcinosarcoma samples. jto.org/article/S1556-0864(2…
Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcin...

Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcin...

In 2025, lung cancer remains the leading cause of cancer-related mortality in both men and women. Although the advent of immunotherapy and targeted therapies has revolutionized the treatment of...

jto.org
1
25
3
85
8,952
🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️@AstraZeneca @OncoAlert @Larvol #EGFR @EGFRResisters astrazeneca.com/media-centre…

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful...

astrazeneca.com
Hidehito HORINOUCHI (@HHorinouchi) profile pictureHidehito HORINOUCHI
@HHorinouchi11 Sep 2023
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as 1st-line Treatment in Pts with EGFRm Advanced NSCLC (FLAURA2) by Prof. Pasi Janne. Very important but huge space open for discussion. We need mature PFS2 and OS to discuss with pts. #LCSM #WCLC23 @IASLC @OncoAlert
Image from Hidehito HORINOUCHI (@HHorinouchi)
Image from Hidehito HORINOUCHI (@HHorinouchi)
Image from Hidehito HORINOUCHI (@HHorinouchi)
Image from Hidehito HORINOUCHI (@HHorinouchi)
1
36
1
111
24,150
Kenn Samala retweeted
d.planchard (@dplanchard) profile picture
d.planchard@dplanchard21 Jul 2025
What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer
Image from d.planchard (@dplanchard)
1
17
1
72
7,346
New research shows that specific co-mutations in KRAS-mutant non-small cell lung cancer may predict better response to ATR inhibitors. Read more: spr.ly/60144IbWM #LungCancer #EndCancer
Specific co-mutations in KRAS-mutant NSCLC improve treatment response

Specific co-mutations in KRAS-mutant NSCLC improve treatment response

Specific co-mutations in KRAS-mutant NSCLC improve treatment response

mdanderson.org
7
22
2,683
Kenn Samala retweeted
yana (@idrinkglory) profile picture
yana@idrinkglory24 Nov 2024
how the "30" era started how it ended
Image from yana (@idrinkglory)
Image from yana (@idrinkglory)
7
653
41
5,412
97,620
Kenn Samala retweeted
PSMO (@cancerexpertsph) profile picture
PSMO@cancerexpertsph15 Aug 2024
Sa kasalukayan, mayroong 377 medical oncologists sa Pilipinas. Ang isang medical oncologist ay isang dalubhasa sa early detection, prevention, diagnosis at treatment ng cancer. Find a medical oncologist near you: bit.ly/findacancerexpert #cancerexpertsph #PSMO
Image from PSMO (@cancerexpertsph)
2
2
73
Dr. Tanasombatkul, a 29 y/o doctor with stage 4 #lungcancer shares that he does not have much time left. He wants others to know “Everyone can get this bc the world has become abnormal, with air & water pollution and various forms of radiation and our genes are ready to mutate"
Thai PBS World (@ThaiPBSWorld) profile pictureThai PBS World
@ThaiPBSWorld5 Nov 2023
Moral support has poured in for Dr. Krittai Tanasombatkul, with his hashtag “Don’t give up” (#สู้ดิวะ) top trending on X today, after he updated his condition as he suffers with his terminal lung cancer, saying he may succumb to the disease in the middle of December. Read more: thaipbsworld.com/moral-suppo… #ThaiPBSWorld #ThailandNews #ThailandUpdate
Image from Thai PBS World (@ThaiPBSWorld)
6
1
19
3,332
“Cancer is responsible for 1 in 6 deaths globally. LMICs will account for the largest number of cases, making research that drives policies to help these countries even more critical” @WHO
Image from Kristina Jenei (@kjmeetswrld)
1
2
2
6
2,138
Come to see our 148 PDX collection resistant to innovative treatments. Ludovic Bigot. @GustaveRoussy #AACR23
Image from Friboulet Luc (@Luc_Friboulet)
1
8
1
26
6,078
Impressive waterfall plots for SHR-A1811 in HER2+ and HER2-low MBC. Responses observed at all dose levels and in patients receiving prior HER2 ADCs. #AACR23
Image from Paolo Tarantino (@PTarantinoMD)
Paolo Tarantino (@PTarantinoMD) profile picturePaolo Tarantino
@PTarantinoMD16 Apr 2023
Jaw-dropping may be a better adjective. ORR 81.5% (88/108) in HER2+ MBC, 55.8% in HER2-low MBC (43/77). The wave of Topo1-ADCs is rising 🌊 eppro02.ativ.me/web/page.php…
3
40
8
148
43,909
The most controversial meta-analysis of the year is now published on @TheLancet. Anthracyclines improved outcomes when added to adjuvant taxanes, but only when administered concurrently. No apparent benefit for sequential schedules, which are current SoC. thelancet.com/journals/lance…
Image from Paolo Tarantino (@PTarantinoMD)
14
98
8
282
47,847
Improvement of 3-year EFS from 43% to 58% with only 3 neoadjuvant infusions of nivo added to neoadjuvant CT for NSCLC. Quite impressive.
Image from Paolo Tarantino (@PTarantinoMD)
Yakup Ergün (@dr_yakupergun) profile pictureYakup Ergün
@dr_yakupergun30 Mar 2023
#ELCC23 Neoadjuvant nivo+platinum-doublet ChT for resectable NSCLC: 3y update from CheckMate 816 Presented by dr @nicogirardcurie 3y EFS➡️57 vs 43% (HR:0.68) 💥Neoadjuvant N+C continues to provide long-term clinical benefit vs C in pts with resectable NSCLC @OncoAlert @myESMO
Image from Yakup Ergün (@dr_yakupergun)
Image from Yakup Ergün (@dr_yakupergun)
1
8
40
9,433
🔥 HUGE news in breast oncology. The #NATALEE phase 3 trial of adjuvant ribociclib for stage II-III breast cancer met the primary endpoint of iDFS! novartis.com/news/media-rele…
Image from Paolo Tarantino (@PTarantinoMD)
10
103
10
315
52,033
Glad to join the many luminaries and influencers at #ESMOAsia22 ! What a fantastic conference ! @myESMO @symplur @ravikanesvaran @peters_solange @TeresaSAmaral @anmwongNZ @SuyogCancer @OncoAlert @matteolambe @herbloong @E_de_Azambuja @KSamalaMD @LorenzaRimassa @StephenVLiu
Image from Rashid Lui 雷諾信 (@RashidLui)
2
9
32
Kenn Samala retweeted
Hope Rugo (@hoperugo) profile picture
Hope Rugo@hoperugo20 Mar 2022
Important article for all breast oncologists to read, and a roadmap for efforts to improve/manage QOL @OncoAlert
FabriceAndre (@FAndreMD) profile pictureFabriceAndre@FAndreMD20 Mar 2022
thank you Matteo. Three trajectoires of global fatigue, including 19% patients "deteriorating". As always, endocrine therapy is a major parameter associated with fatigue, together with BMI and age (tables below are extracts, not the full table)
Image from FabriceAndre (@FAndreMD)
Image from FabriceAndre (@FAndreMD)
Image from FabriceAndre (@FAndreMD)
10
38
Kenn Samala retweeted
OncoViews (@OncoViews) profile picture
OncoViews
@OncoViews15 Mar 2022
🚨#Amivantamab has been approved by @Swissmedic_ for adults with #NSCLC with activating EGFR ex20ins mutations, after the failure of platinum-based therapy! Amivantamab is the first targeted therapy for this subset of #NSCLC 🫁 Check out more ➡️ bit.ly/35SjiDD
Image from OncoViews (@OncoViews)
1
8
1
19
11. Lastly, treat your patients how you would want your own family member treated. #MedTwitter #ArtofMedicine #WordsMatter @tmprowell @marklewismd @tarasanftmd @l_schapira 8/fin
42
60
12
1,116
Load more